PDSB vs. CGEN, PLRX, OCGN, INBX, NBTX, CRGX, ENTA, INMB, ALEC, and PLX
Should you be buying PDS Biotechnology stock or one of its competitors? The main competitors of PDS Biotechnology include Compugen (CGEN), Pliant Therapeutics (PLRX), Ocugen (OCGN), Inhibrx (INBX), Nanobiotix (NBTX), CARGO Therapeutics (CRGX), Enanta Pharmaceuticals (ENTA), INmune Bio (INMB), Alector (ALEC), and Protalix BioTherapeutics (PLX). These companies are all part of the "pharmaceutical products" industry.
PDS Biotechnology vs.
PDS Biotechnology (NASDAQ:PDSB) and Compugen (NASDAQ:CGEN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, community ranking, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.
Compugen received 237 more outperform votes than PDS Biotechnology when rated by MarketBeat users. However, 69.90% of users gave PDS Biotechnology an outperform vote while only 64.38% of users gave Compugen an outperform vote.
26.8% of PDS Biotechnology shares are owned by institutional investors. Comparatively, 12.2% of Compugen shares are owned by institutional investors. 9.5% of PDS Biotechnology shares are owned by company insiders. Comparatively, 9.5% of Compugen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Compugen has a net margin of 2.67% compared to PDS Biotechnology's net margin of 0.00%. Compugen's return on equity of 2.62% beat PDS Biotechnology's return on equity.
Compugen has higher revenue and earnings than PDS Biotechnology. PDS Biotechnology is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.
PDS Biotechnology has a beta of 1.88, indicating that its stock price is 88% more volatile than the S&P 500. Comparatively, Compugen has a beta of 2.65, indicating that its stock price is 165% more volatile than the S&P 500.
In the previous week, Compugen had 3 more articles in the media than PDS Biotechnology. MarketBeat recorded 9 mentions for Compugen and 6 mentions for PDS Biotechnology. PDS Biotechnology's average media sentiment score of 0.84 beat Compugen's score of -0.16 indicating that PDS Biotechnology is being referred to more favorably in the media.
PDS Biotechnology currently has a consensus target price of $11.67, suggesting a potential upside of 804.39%. Compugen has a consensus target price of $4.00, suggesting a potential upside of 138.10%. Given PDS Biotechnology's stronger consensus rating and higher probable upside, research analysts clearly believe PDS Biotechnology is more favorable than Compugen.
Summary
Compugen beats PDS Biotechnology on 10 of the 17 factors compared between the two stocks.
Get PDS Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for PDSB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PDS Biotechnology Competitors List
Related Companies and Tools
This page (NASDAQ:PDSB) was last updated on 3/4/2025 by MarketBeat.com Staff
Free PDSB Stock Alerts